Podcasts about sle

Et si votre obsession pour la réussite financière était exactement ce qui vous empêchait d'avancer ?Dans cette séance de Dépolarisation® mentale filmée en direct, j'accueille Bart — entrepreneur, podcasteur et athlète qualifié au championnat du monde — qui se sent bloqué dans son business et convaincu qu'il lui faut absolument un associé pour passer à l'étape suivante.Ce qu'on découvre ensemble au fil de la séance est bien plus profond : une croyance ancrée autour de l'argent, deux associations passées qui ont laissé des traces, et une liberté de vie qu'il ne s'autorise pas à reconnaître comme une vraie richesse.Au programme de cette séance :Pourquoi vouloir un associé à tout prix peut être un signal d'alarmeComment une ancienne association "ratée" peut cacher des bénéfices insoupçonnésLe piège de confondre richesse financière et richesse de vieCe que la Dépolarisation® révèle sur nos vraies valeurs et nos vraies prioritésPensez à liker ce podcast s'il vous a plu et le partager autour de vous ;-)

In this episode of the Lupus Foundation of America's The Expert Series podcast, we focus on how steroids are an essential and often life-saving treatment for people with lupus, even though the new SLE guidelines recommend using them as little as possible. Our guest speaker, Dr. Megan Lockwood, walks us through why steroids play such a critical role in lupus care, the potential risks and downsides of prolonged use and why limiting their use whenever possible is equally important. We also discuss how patients can work with their health care providers to develop a thoughtful, personalized steroid plan and have productive conversations with their doctors about managing steroid treatment.Sign up to receive emails from the Lupus Foundation of America (LFA) when new episodes are published: https://support.lupus.org/site/SPageNavigator/email_subscribe_expert_series.htmlThis episode will help you understand:How steroid mechanism of actionThe importance of minimizing steroid useShort and long-term side effects of steroidsAlternatives to steroids in lupus treatmentSafe steroid tapering strategiesFuture treatments and research developmentsRelated Resources:Ask a Lupus Health Educator (LFA): https://www.lupus.org/care-support/ask-a-health-educatorFind Support Near You (LFA): https://www.lupus.org/resources/find-support-near-youNational Resource Center on Lupus (LFA): https://www.lupus.org/resourcesThe Expert Series (LFA): https://www.lupus.org/resources/lupus-the-expert-seriesMedications Used to Treat Lupus (LFA): https://www.lupus.org/resources/medications-used-to-treat-lupus

This podcast has been funded by an educational grant from Viatris. Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease shaped by dysregulated immune pathways, variable organ involvement, and substantial patient burden. In this educational podcast, Anca Askanase explores how a deeper understanding of SLE immunology can help rheumatologists contextualize disease activity, evolving research, and guideline-based care. Topics covered: Key immune pathways involved in SLE pathophysiology, including innate and adaptive immune dysregulation  How pathway biology may help explain clinical heterogeneity and differences in disease activity between patients  What rheumatologists should consider when interpreting emerging pathway-based research and cross-disease immunology concepts  How current guideline-based care frames treatment goals, patient burden, and the evolving focus on remission in SLE  Speakers Anca D. Askanase, Chair, Department of Medicine, and Chief, Division of Rheumatology, Hospital for Special Surgery, New York, USA

2026 EULAR Preview CAR-T For Rheumatoid Arthritis What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM How Many CAR-Ts Do We Need to Test Drive?

BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs

Systemic Lupus Erythematosus (SLE) explained, including pathophysiology, causes and a mnemonic for SLE symptoms (SOAP BRAIN MD). We also cover the EULAR / ACR diagnostic criteria for SLE, as well as SLE treatment. PDFs available at: https://rhesusmedicine.com/pages/rheumatologyConsider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps 0:00 What is SLE? (Systemic Lupus Erythematosus)1:02 SLE Pathophysiology3:08 SLE Causes4:21 SLE Symptoms (SLE Mnemonic SOAP BRAIN MD)7:13 SLE Diagnosis (EULAR & ACR criteria)9:22 SLE TreatmentLINK TO MNEMONICS:https://www.youtube.com/watch?v=p-XE7PiwGgE&list=PLGNSE_HvIV4t7a33bbHN1fq-j_tge0GmpLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesBMJ Best Practice (2025) Systemic lupus erythematosus – Symptoms, diagnosis and treatment. BMJ Best Practice. Available at: https://bestpractice.bmj.com/topics/en-gb/103Lupus Foundation of America (n.d.) The history of lupus. Lupus Foundation of America. Available at: https://www.lupus.org/resources/the-history-of-lupusEdRheum (n.d.) Systemic lupus erythematosus. EdRheum. Available at: https://edrheum.org/systemic-lupus/MSD Manual Professional Edition (2025) Systemic lupus erythematosus (SLE). MSD Manual Professional Edition. Available at: https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/systemic-rheumatic-diseases/systemic-lupus-erythematosus-slePlease remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. 

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared goal of greater precision in immune modulation.

Un projet d'investissement locatif ? Prenez RDV gratuitement avec Artae immobilier

Vos données vendues par GM + les pires routes du QuébecTORQ | Épisode 566Dans cet épisode de TORQ, on parle de deux sujets qui touchent directement les automobilistes : le scandale entourant General Motors, OnStar et la vente de données de conduite, ainsi que le nouveau palmarès des pires routes du Québec publié par CAA-Québec pour 2026.GM devra payer une amende de 12,75 millions $ US en Californie après des accusations liées à la vente de données personnelles de conducteurs. Les informations concernées incluraient des données comme la localisation GPS, la vitesse, les accélérations brusques et les habitudes de conduite. Ces données auraient été partagées avec des courtiers de données comme LexisNexis Risk Solutions et Verisk Analytics, des entreprises liées à l'analyse de risque et au monde de l'assurance.Est-ce que votre véhicule moderne vous surveille? Est-ce que vos données de conduite peuvent influencer vos assurances? Et surtout, est-ce que les propriétaires de véhicules GM seront dédommagés?On regarde aussi le palmarès 2026 des pires routes du Québec selon CAA-Québec. Cette année, l'Outaouais domine le classement avec plusieurs routes de Gatineau parmi les pires de la province, dont le chemin Pink, le chemin Klock et le boulevard Saint-Raymond. Montréal, Laval, Québec, la Montérégie, la Mauricie, le Bas-Saint-Laurent et plusieurs autres régions sont aussi touchées par l'état des routes, les nids-de-poule et les coûts que ça impose aux automobilistes.Dans cet épisode :GM, OnStar et la vente de données de conduiteL'amende de 12,75 millions $ US contre General MotorsLes données vendues à LexisNexis et VeriskLe lien possible avec les assurances automobilesLa question de la vie privée dans les véhicules connectésLe palmarès CAA-Québec 2026 des pires routesLes routes les plus problématiques au QuébecPourquoi les automobilistes paient encore la factureLes voitures modernes sont de plus en plus connectées, mais est-ce que ça veut dire que les conducteurs perdent le contrôle de leurs données? Et pendant ce temps, au Québec, les routes continuent de coûter cher aux citoyens avec les nids-de-poule, les suspensions brisées, les pneus éclatés et les réparations.Abonnez-vous à JUL TORQ pour plus d'actualités automobiles, analyses, essais routiers, opinions et nouvelles du marché automobile au Québec, au Canada et en Amérique du Nord.#GM #Québec #JULTORQ

L'alternance est souvent présentée comme idéale pour les adolescents avec un TDAH… et c'est parfois vrai. Mais ce format demande aussi de l'autonomie, de la gestion et une bonne capacité d'adaptation. Dans cet épisode, on vous aide à comprendre si c'est vraiment adapté à votre enfant.✅ DANS CET ÉPISODE NOUS ABORDONS :Le vrai potentiel de l'alternance pour les profils TDAHLes difficultés souvent sous-estimées (charge, transitions, autonomie)Les 3 questions clés à se poser avant de déciderLe rôle déterminant du tuteur en entrepriseLes secteurs plus ou moins adaptésLe rôle des parents pour sécuriser le parcours

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z 2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs 3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z 4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY 5. Predictors of Calcinosis Cutis in Systemic Sclerosis   6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB 7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N 8. Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://buff.ly/BsM7NKQ 9. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis - Review 10. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis 11. Brepocitinib in Dermatomyositis

In this episode our host Dr Raquel Faria discusses two challenging cases with Professors Maria Dall'Era andRonald van Vollenhoven of the Lupus Academy Steering Committee. The two cases include:1. Myositis, ILD, and the long-term lupus patient whose long-term management never truly stays in one box.2. The nuances of a "slow-burn" pediatric-to-adult SLE transition, focusing on the diagnostic challenges of the "pre-lupus" label and the management of high-interferon phenotypes.Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines for patients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.

Hey there, cosmic voyagers! This episode is off-the-wall fascinating—get ready to rocket into a topic most folks think is 400% impossible: living with 80-90% less food. I'm Eden, your host and fellow spiritual experimenter, and I just completed the breatharian initiation with none other than Ray (yes, the tall, grounded, “man's man” breatharian guide whose last name literally means “bringer of light”—how perfect is that?!). Ray is joining us from Tel Aviv—in the middle of a literal war zone—to talk about embracing hope, living fueled by prana instead of pizza, and how he went from Israeli military man to globe-traveling, fasting sage (seriously, we're talking 10 days, no food and no water—science says “no way,” but his cells clearly missed the memo).We'll dive into:-What “new earth” could mean (and are we already LIVING it?).-How breatharianism shakes up everything you thought about food, energy, and spiritual evolution.-Emotional eating, food freedom, and breaking those dinner-table rules handed down from mama.-The very real, very quirky science and wild personal experiments behind it all (would you eat only cake and still feel fabulous? Ray tried it.)-And yes—galactic connections, weird “coincidences,” parallel universes, and reprogramming your matrix-y mind.-As always, we wrap up with our signature Just Be Practice—this time, Ray guides us through a Parallel Universes manifestation exercise. Connect with Ray:Website: https://raymaor.comYouTube: https://www.youtube.com/@RayMaorFacebook: https://www.facebook.com/ray.maor.9Breathanrian Part 1 & 2:https://www.youtube.com/watch?v=64jNM7lx030https://www.youtube.com/watch?v=GFDitb3bhQ4TV appearance with no food or water for a duration of 8 days:http://raymaor.com/8dayexperiment Time Stamps:04:00 Overcoming impossible challenges together07:46 Ray's opinion on New Earth9:34 Being in a War Zone11:34 Reflecting on self-awareness journey13:52 Ray finding his Breatharian teacher/21 days/then him becoming a teacher19:18 Weight loss through the process/body appreciation22:15 Initiation, initial disbelief wi*Host Eden Koz is a New Earth & soul realignment specialist. She also performs spiritual Co#id Vac+ Healings. See her new package offerings to help you ascend into a New Earth human.**Additionally, if you are questioning your Gold IRA because of potential scams (see EP188) or want to invest in a precious metals company with integrity...email: info@milesfranklin.com and put "Eden" in the subject lineMiles Franklin website: https://milesfranklin.com Contact info for Eden Koz  / Just Be®, LLC:Website: EdenJustBe.com Socials: TikTok, FB, FB (Just Be), X, Insta, LinkedInJust Be~Spiritual BOOM Podcast - Video Directories: BitChute, Rumble, YouTube, Odysee, ...

Send us Fan MailAI didn't just make deepfakes easier. It made targeted sexual abuse scalable. I open with a Wired-reported reality that's hitting schools worldwide: AI tools that can generate fake nude images from ordinary photos, spread through bots and subscription services, and leave students and families dealing with humiliation, harassment, and real trauma. If you're a cybersecurity professional, this is a moment where your skills can protect your community, not just your company.I walk through concrete ways to help: offering free threat briefings to school districts, helping draft acceptable use and AI governance policies, adding mandatory reporting language, and building age-appropriate deepfake awareness training for staff and students. If you're in threat intelligence, you can document and report active infrastructure. If you're in GRC or vendor risk, you can push synthetic media controls and stronger AI governance. I also talk about incident response basics for schools: evidence collection, platform takedowns, and tabletop exercises that prepare teams for a fast-moving crisis.Then we pivot into CISSP exam prep with practical questions tied to today's threats. We break down quantitative risk assessment (ALE, SLE, ARO) and how cost of mitigation drives the right response. We hit GDPR Article 22 and AI transparency, post-quantum cryptography for long-term retention, SSD sanitisation aligned to NIST 800-88 using cryptographic erasure, and zero trust in 5G edge networks using software-defined perimeter controls for least privilege IoT communications.Subscribe for weekly CISSP training, share this with someone who works with schools, and leave a review so more defenders can find it.Gain exclusive access to 360 FREE CISSP Practice Questions at FreeCISSPQuestions.com and have them delivered directly to your inbox!  Don't miss this valuable opportunity to strengthen your CISSP exam preparation and boost your chances of certification success. Join now and start your journey toward CISSP mastery today!

Send us Fan MailCheck us out at:  https://www.cisspcybertraining.com/Get access to 360 FREE CISSP Questions:  https://www.cisspcybertraining.com/offers/dzHKVcDB/checkoutGet access to my FREE CISSP Self-Study Essentials Videos:  https://www.cisspcybertraining.com/offers/KzBKKouvAn AI model that can uncover thousands of zero-days and potentially chain multiple vulnerabilities into an automated exploit is not just a scary headline, it's a stress test for every risk program on the planet. I open with what the Mythos news implies for real-world defense: attacker behavior may shift from human pace to machine speed, and many SIEM and EDR detections are still tuned for human patterns. That's why we talk candidly about what security teams may need to do next, including tightening externally facing systems and moving faster toward a zero trust architecture. Then we pivot into CISSP Domain 1 risk management concepts, translating exam language into decisions you'll actually make in a business. We define the core terminology like assets, threats, vulnerabilities, exposure, safeguards, attacks and breaches, then walk through control categories (technical, administrative, physical) and control types (preventive, detective, corrective, deterrent, recovery and compensating). If you've ever wondered why risk conversations go sideways, we also dig into the difference between risk appetite, risk capacity, and risk tolerance, and why you can't set these without business leaders in the room. We also tackle quantitative risk analysis versus qualitative risk analysis, including CISSP formulas such as AV, EF, SLE, ARO and ALE, plus a critical reality check on “fake precision” and how to apply a cost-benefit analysis that holds up. Finally, we cover security control assessments, monitoring and measurement, building a risk register safely, and how maturity models and risk frameworks like CMMI, ISO 31000, NIST approaches, ISO 27005, COBIT, SABSA and PCI DSS fit into a defensible cybersecurity risk management program. Subscribe, share this with a CISSP study partner, and leave a review so more security pros can find the show.Gain exclusive access to 360 FREE CISSP Practice Questions at FreeCISSPQuestions.com and have them delivered directly to your inbox!  Don't miss this valuable opportunity to strengthen your CISSP exam preparation and boost your chances of certification success. Join now and start your journey toward CISSP mastery today!

➡️ Tu veux investir dans l'immobilier en Suisse ? Conseils, analyses et rendez-vous ici : https://taap.it/fixer_unrendezvousL'After, le podcast qui aide les investisseurs à comprendre le marché immobilier et le business en Suisse.Dans cet épisode, on s'attaque à une question centrale pour les investisseurs et les propriétaires immobiliers :

Le yoga nous invite à rentrer en nous-mêmes. Alors pourquoi finit-on par se déshabiller pour exister sur Instagram ?Dans cet épisode, je soulève un sujet qui m'agace profondément : l'hypersexualisation du yoga postural. Pas un scroll sans une posture lascive, une vue sur les fesses ou les seins. Et ce qui m'agace, ce n'est pas seulement l'image — c'est que ça devient la norme.Je suis de la génération 80. Celle où les femmes à moitié vêtues vendaient des yaourts et des voitures. On a cru que les choses avaient changé: MeToo, diversité des corps, prises de conscience collectives. Et puis le phénomène est revenu, habillé en legging et tapis de yoga.On remonte ensemble le fil : comment le yoga postural s'est construit sur des codes occidentaux : corps mince, blanc, souple, jeune. Comment Instagram n'a pas créé l'hypersexualisation, mais l'a récompensée et normalisée. Et comment tout ça finit par nous faire exister uniquement dans le regard des autres, au point que les téléphones s'invitent maintenant jusque dans les cours, parce que sans la caméra, la pratique semble ne pas exister.Je parle aussi de ce que ça coûte de résister. Parce que dire non à ces codes, c'est choisir une forme d'invisibilité. Moins de reach, moins de likes, le doute qui s'installe. Mais refuser de se dévêtir pour être visible, refuser de sexualiser sa pratique pour plaire à un algorithme — c'est un acte pédagogique et politique.On vaut bien mieux que ça. Le yoga vaut bien mieux que ça.Dans cet épisode on aborde :L'hypersexualisation du yoga postural sur les réseaux sociauxLe voyage du yoga de l'Inde vers l'Occident et les codes qui s'y sont greffésLe rôle de l'algorithme Instagram dans la normalisation du corps-objetLe prix de la résistance pour les enseignant·es qui refusent ces codesComment exister par ce qu'on a à l'intérieur, pas dans le regard des autresPour poursuivre l'aventure, rejoignez la Newsletter qui s'adresse aux profs de Yoga.

This month: Multiple FDA regulatory decisions germane to dermatology, psoriasis and lupus; and Eosinophilic Fasciitis (EF) reminder and should you worry about fibromyalgia? Show Notes: 1. FDA Approves Icotrokinra for Plaque Psoriasis The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx 2. FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged 12yrs) with moderate to severe hidradenitis suppurativa  https://t.co/oX4LGU16QP 3. FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7 4. TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS 5.vUCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi 6. Retrospective TriNetX Network cohort study of adult PsA (N 123,031) pts, propensity- matched to non-PsA controls. PsA had signif higher CV morbidity: MACE (HR 1.74); mortality (HR 1.95); CHF (HR 1.96), MI (HR 1.71), & CVA (HR 1.49). bDMARDs reduced MACE (HR 0.95) & mortality (HR 0.92) vs csDMARDs   https://t.co/bHrq9KpwBM 7. Prevalence of fibromyalgia in PsA = 18%. FM-PsA pts have higher scores Dz activity scores from FM, rather than inflammation. Fibromyalgia is assoc w/ worse disease outcomes, including failure to achieve low disease activity state and poorer response to therapy. https://t.co/utQRXPmpDs 8. JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/WEFFITtmQC 9. REVEAL, a 5-yr real-world study of 236 SLE pts initiating anifrolumab (basekbube SLEDAI-2K 7 for mucocutaneous (67%) & MSK (49%) dz. At 6 months, 26% achieved remission, 66% reached LLDAS, and 57% achieved LLDAS5. Authors claim rapid onset of action https://t.co/16OQatOcPj https://t.co/mU9aciCNcH 10. Update on FDA complete response letter to AZ regarding BLA hold for anifrolumab (Saphnelo) for SC use in SLE. CRL originally issued 10/10/25, but announced 2/3/26. FDA CRL cites critical data quality w/ key analyses in SC-TULIP study. A BLA decision expected in 1st half of 2026 https://t.co/zuwtsdL6I9 11. NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus https://rheumnow.com/news/nejm-obinutuzumab-active-systemic-lupus-erythematosus

Drs. Petri and Woolfson discuss a simple risk score using autoantibodies, complement, and demographics to predict which SLE patients are most likely to develop proteinuria and lupus nephritis. They also highlight evidence showing that earlier kidney biopsies at lower proteinuria levels, especially in patients with low complement, can detect serious disease sooner and improve outcomes.

Three studies highlight new findings: A phase 3 trial showed obinutuzumab significantly improved lupus responses versus placebo in active SLE patients on standard therapy. A trial of finerenone in type 1 diabetes with chronic kidney disease demonstrated meaningful reductions in albuminuria compared to placebo, suggesting a new renal-protective option. Finally, paired pediatric trials found that adding acetaminophen or hydromorphone to ibuprofen provided no additional pain relief for children's acute limb injuries, with opioids causing four times more adverse events. Ibuprofen alone remains the recommended first-line approach.

En este episodio, Brian, Tom y Matt Galsky analizan los datos del estudio B15 sobre terapia neoadyuvante para el cáncer de vejiga músculo-invasivo cisplatino-elegible, centrándose en la eficacia de EV-Pembro en comparación con cisplatino-gemcitabina. Exploran la SLE, SG y las implicaciones de la duración del tratamiento así como su individualización. La conversación también aborda el papel del ctDNA en las decisiones terapéuticas, las histologías alternativas y la importancia de la terapia sistémica neoadyuvante. El episodio concluye con reflexiones sobre las futuras direcciones en el tratamiento del cáncer de vejiga y la relevancia de los estudios en curso.

Drs. Petri and Woolfson review the American College of Rheumatology Convergence 2025 data that suggest belimumab might lower mortality in SLE compared with traditional oral immunosuppressants, supporting earlier biologic use. They also discuss an observational study in lupus nephritis that links GLP-1 agonists to better kidney, survival, and cardiovascular outcomes than SGLT2 inhibitors, particularly in overweight patients.

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76 Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27)   https://t.co/1REWmod73W Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM

The Southeastern Livestock Exposition (SLE) was created by cattlemen in the 1950s to support Alabama agriculture through youth programs. Join SLE Executive Director Sarah Hunter, SLE President Linwood McClain and host Josie Jones as they discuss the history and mission of the SLE and how this heritage stays strong through the group's biggest event of the year. Hear more about youth agricultural programs hosted during SLE Rodeo & Livestock Week and the many NEW activities that will be available at the 2026 event for Alabama's rodeo fans.  Finally, listen to the end for a special money-saving ticket tip and some details on this year's specialty act. Members of the SLE hope to see you there!

In this episode host Dr. Raquel Faria (Portugal) is joined by Professors David Isenberg (UK) and Ricard Cervera (Spain) to navigate the high-stakes complexities of haematological manifestations in SLE.  Through the lens of two remarkable 20-year patient journeys, the experts explore the "coagulation tightrope"—the life-threatening balance between aggressive systemic clotting and profound bleeding risks.Disclaimer: ‘During Lupus Academy podcast episodes, participants may refer to off label use of medicines for patients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.'

Cette semaine, on parle de nos problèmes de personnes de plus de 24 ans.Pour écouter le 5ème Quarts d'Heure, abonnez-vous à Supercast comme ceci : https://4quartsdheure.supercast.com/Abonnez-vous à 4 Quarts d'Heure sur votre plateforme préférée : https://tr.ee/MEaR8W9S9GLes ups et les downs :Le down d'Alix : rester connectée avec ses ami.e.s parent.e.sLe rollercoaster d'Adrien : se prendre un tunnel par son osthéo Le down de Louise : ne pas goûter son Mapo doufu Le up de Camille : emprunter les chiens des gensEt retrouvez notre invité Adrien sur instagramDans cet épisode, on parle de : Cette série : GirlsCe film : 500 jours ensembleCe podcast : Hot Girls OnlyCe site : Emprunte mon toutou.comSuivez-nous sur Instagram :4 Quarts d'Heure : @4quartsdheureLouise : @petrouchka_Alix : @alixmrtnCamille : @camille.lorenteL'équipe de prod :Au montage de cet épisode Alphonse GausslinAu mixage et à la prod Zu Aux réseaux Coline Jamaitet merci à Acast pour le studio Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Today we welcome Sarah Jane to the R2Kast

Turpinām tradīciju raidījumā - iepazīt jauno sociālantropologu pētījumus. Šogad to vidū ir gan nēģu zveja Salacgrīvā, gan sociālantropoloģiski novērojumi bērnu rotaļlaukumus, gan zaļo inovāciju ieviešana slimnīcu vidē. Sociālā antropoloģija ir tāda interesanta nozare, kas palīdz labāk izprast cilvēkiem pašiem sevi. Kādi tad mēs esam, kā veidojas mūsu attiecības citam ar citu un apkārtējo vidi - tas viss nonāk sociālantrolologu uzmanības lokā. Ar saviem pētījumiem iepazīstina Rīgas Stradiņa Universitātes sociālantropoloģes Līga Sleņģe, Signe Nikolājeva un Zanda Gailuma-Zohra, kuras izstrādājušas savus maģistra darbus.  Iepazīstam gada augu – lāceni un gada koku – parasto ievu Interesanti, ka gan Botāniķu biedrība, izvirzot lāceni par gada augu, un attiecīgi Dendrologu biedrība gada koka titulu piešķirot ievai, nav to darījuši tāpēc, ka minētie nominanti būt īpaši apdraudēti vai paši kam dabā kaitējuši. Iemesls ir, lai vairāk izpētītu un uzzinātu par to stāvokli dabā un dzīvotnēm, kur mīt ieva un lācene. Sākam ar gada augu – lāceni, saldo dzintardzelteno purva ogu. Kā teic Latvijas Botāniķu biedrības pārstāve un šī gada auga nominanta izvirzītāja Vija Kreile, tad lācene nav reta oga, tomēr ne viscaur purvā tā ir sastopama. Šī gada laikā botāniķi centīsies noskaidrot, kā purva izmēri, konkrēti purva malas,  nosaka lāceņu daudzumu šajā dzīvotnē. Interesējamies arī, kāpēc lāceņu ievārījums ir krietni dārgāks, salīdzinot ar citiem šādiem kārumiem burkās. Vēl skaidrojumu par minētajām ogām sniedz Latvijas Botāniķu biedrības valdes priekšsēdētāja Anete Pošiva-Bunkovska. Gada koks – parastā ieva ir gan upju palieņu veselības indikators, gan viegli indīgs, tomēr ārstniecības augs un diezgan labi tiek galā ar savu kaitēkli – tīklkodi. Vairāk ar parasto ievu iepazīstina Latvijas dendrologu biedrības valdes pārstāvis Gvido Leiburgs. -- Par dzelteno stērsti stāsta ornitologs, Latvijas Ornitoloģijas biedrības priekšsēdētājs Viesturs Ķerus.  

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1

Since this episode was released for the first time in May 2023, two recent studies of note have been published, providing an important update on patients' experiences of SLE in Latin America and Europe. These publications are summarisedbelow (full publications are available online):Study Summary:The Patient Experience of SLE in Latin AmericaQuintana R, et al. Living with systemic lupus erythematosus in 2024: Latin American experience based on a patient survey. Clin Rheumatol. 2025 Dec 5. doi: 10.1007/s10067-025-07867-1. This 2024 GLADEL network survey of 1,180 Latin American patients reveals a profound "well-being gap" in Systemic Lupus Erythematosus (SLE) care. While 80.9% receive antimalarials and two-thirds feel "controlled," clinical stability masks a pervasive psychosocial crisis. The data shows that 60% of patients suffer from anxiety or depression, and 62.1% report significant professional or educational setbacks. Physical burdens remain high, including joint involvement (71.4%), skin issues (47.4%), and life-altering renal complications (37.5%). Furthermore, 43.7% noted negative impacts on emotional and sexual health.Despite heavy reliance on corticosteroids (55.7%), uptake of newer biologics remains low at 11.1%. These findings serve asa critical call for Latin American healthcare systems to adopt a "Treat-to-Target" model. This approach must move beyond mere symptom management to prioritize the restoration of a patient's social, mental, and professional agency. Study Summary:Unmet Needs of SLE Patients in EuropeCornet A, et al. Experiences and unmet needs of persons living with systemic lupus erythematosus in Europe: LupusEurope's 2024 Swiss knife survey. Autoimmun Rev. 2025 Jul 31;24(8):103838. doi: 10.1016/j.autrev.2025.103838. The 2024 "Swiss Knife" survey by Lupus Europe reveals a significant "perception gap" among 4,525 patients across 36 countries. While 66.5% believe their lupus is "under control," only 7.9% remained flare-free over five years, indicating a normalization of chronic symptoms.Several unmet needs remain. The study found that fatigue is the most prevalent symptom (84.9%) but remains the least addressed in clinical plans. Joint and muscle pain also remain high. Patients seek remission or low disease activity, yet 32% lack access to essential non-pharmacological therapies like physiotherapy. Over 31% report insufficient consultation time, often leaving discontent unvoiced.  Finaly, adoption of digital health tools remains low at 14.3%.The survey concludes that European SLE management must shift toward patient-centered care, prioritizing better physician-patient communication and digital health integration to address the disease's true physical and psychological burden.In this episode Dr Raquel Faria is speaking with Jeanette Andersen (Chair of Lupus Europe) and Professors Ricard Cervera and Maria Dall'Era.You can visit the Lupus Europe website here: ⁠https://www.lupus-europe.org/⁠Disclaimer: ‘During Lupus Academy podcast episodes, participants may refer to off label use of medicines for patients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.'

In this episode of the Lupus Foundation of America's The Expert Series podcast, Dr. Cindy Aranow discusses the newly released American College of Rheumatology treatment guidelines for systemic lupus erythematosus (SLE). She explains the importance of these guidelines in providing evidence-based recommendations for individualized patient care, the process of developing and updating the guidelines and key changes that emphasize optimal disease control and reducing long-term steroid use. Dr. Aranow highlights the need for patient engagement and communication with health care providers to ensure effective management of lupus.This episode of The Expert Series was sponsored by AstraZeneca. The Lupus Foundation of America would like to thank AstraZeneca for their support of education programs for people with lupus.Sign up to receive emails from the Lupus Foundation of America (LFA) when new episodes are published: https://support.lupus.org/site/SPageNavigator/email_subscribe_expert_series.htmlEpisode Takeaways:Treatment guidelines are recommendations, not mandates, and support - not replace - your doctor's clinical judgment.Lupus is a highly individualized disease, so care must be tailored to each person.A diverse group of experts develops and regularly updates guidelines based on new research.Guidelines help clinicians navigate complex and evolving medical evidence.Recent guidelines emphasize achieving remission or low disease activity while reducing long-term steroid use.Open communication and active patient involvement are essential for effective treatment decisions. Related Resources:Ask a Lupus Health Educator (LFA): https://www.lupus.org/care-support/ask-a-health-educatorFind Support Near You (LFA): https://www.lupus.org/resources/find-support-near-youNational Resource Center on Lupus (LFA): https://www.lupus.org/resourcesThe Expert Series (LFA): https://www.lupus.org/resources/lupus-the-expert-seriesNew Lupus Treatment Guidelines (ACR): https://rheumatology.org/press-releases/new-lupus-sle-clinical-practice-guidelines-released

In this episode of HSS Presents, rheumatologist Dr. Caroline Siegel is joined by HSS colleagues Dr. Lisa Samaritano and Dr. Jane Salmon to discuss managing pregnancy for patients with autoimmune rheumatic diseases. They emphasize that most patients have successful pregnancies, but conditions like systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) carry greater risks, including preeclampsia and placental insufficiency. Successful outcomes rely on preconception planning, which includes achieving quiescent disease for about six months on pregnancy-compatible medications and screening for antibodies. Dr. Salmon also shares exciting clinical trial results using a TNF inhibitor to improve pregnancy outcomes in high-risk APS patients.

Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow.com.  B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs.

A 32-year-old woman with systemic lupus erythematosus (SLE) presents with a new onset proximal muscle weakness, facial rounding, and abdominal striae. The patient reports long-term use of oral prednisone for SLE management. Which of the following conditions is the most likely cause of her symptoms? Find it all out in the podcast! Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects. #Npte #PT #ptboards #crushtheNPTE #study #studygram #spt #ptstudent #ptlife #sptprobs #physicaltherapystudent #physicaltherapy #physio #physiotherapist #ptlife #ptstudentstudy

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES 1. Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron's, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV 2. Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9 3. Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of 19 w/ SLE & 5 w/ CLE; these were older (65 yrs), more male (15M/9F), w/ less renal [10%] & articular [36%] Dz w/ less dsDNA [32%]. Thought to be clonal inflammatory, & not autoinflammatory, process. https://t.co/EAvkJm6GQs 4. Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxnhttps://t.co/2qa7O2v6fm 5. No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj 6. Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww 7. Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1). 8. 25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/CYwVy7ls7y 9. ACR2025 Non-Renal Lupus Guidelines – from ACR Convergence 2025 10. 900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the 900,000  https://t.co/o7BaWjS4HB

Comment réinventer les talents à l'ère de l'IA ?Dans cet épisode, je reçois Léa , speaker et entrepreneure, qui travaille depuis plus de dix ans sur les liens entre technologie et développement des talents. Après son intervention au Global Peter Drucker Forum, elle partage avec nous ce que l'intelligence artificielle change — ou devrait changer — dans notre façon de former, manager, et valoriser les individus dans les organisations.Léa nous propose un autre regard sur les juniors, l'engagement, les biais de recrutement, l'éducation, et même la parentalité, en montrant comment l'IA peut devenir un levier… ou un piège. C'est une conversation dense, où on parle autant de soft skills que d'architecture des systèmes RH, et où la voix humaine reprend toute sa place.Ce que vous allez entendre :Pourquoi il faut repenser le leadership à l'ère des outils intelligentsComment l'IA redéfinit la notion de “talent” et de “performance”Le risque d'un marché du travail qui marginalise les jeunes et les profils atypiquesLe lien entre parentalité et management en contexte IAiséL'impact d'une IA mal utilisée sur l'engagement des collaborateursPourquoi les grandes écoles freinent l'adoption de l'IALe danger de confondre automatisation et progrèsLe rôle des entreprises dans l'alphabétisation à l'IACe que cache vraiment le storytelling alarmiste autour de l'intelligence artificielleLes dérives possibles quand l'IA devient co-parent à la maisonConclusion :Ce n'est pas l'IA qu'il faut craindre, mais la manière dont on l'intègre. Pour Léa, l'enjeu est de renforcer notre capacité individuelle à évoluer, apprendre, décider. Et redonner une vraie place à l'humain.

Well, from time to time we cover RANDOM tidbits of information which cover RANDOM questions and/or RANDOM patient care issues that we encounter. In this episode we will cover one OB issue related to recurrent pregnancy loss, one GYN issue related to unilateral breast swelling in a patient with SLE, and one RANDOM life perspective response from a mock interview that I participated in for a residency candidate. Listen in fordetails!1.     Viviana DO; Giugni, Claudio Schenone MD; Ros, Stephanie T. MD, MSCI. Factor V and recurrent pregnancy loss: de Assis, Evaluation of Recurrent Pregnancy Loss. Obstetrics & Gynecology 143(5):p 645-659, May 2024. | DOI: 10.1097/AOG.0000000000005498Unilateral Breast Swelling with SLE: 2.     Voizard B, Lalonde L, Sanchez LM, et al. LupusMastitis as a First Manifestation of Systemic Disease: About Two Cases With a Review of the Literature. European Journal of Radiology. 2017;92:124-131. doi:10.1016/j.ejrad.2017.04.023.3.     Kinonen C, Gattuso P, Reddy VB. Lupus Mastitis:An Uncommon Complication of Systemic or Discoid Lupus. The American Journal of Surgical Pathology. 2010;34(6):901-6. doi:10.1097/PAS.0b013e3181da00fb.4.      Summers TA, Lehman MB, Barner R, Royer MC. Lupus Mastitis: A Clinicopathologic Review and Addition of a Case. Advances in Anatomic Pathology.2009;16(1):56-61. doi:10.1097/PAP.0b013e3181915ff7.5.     Jiménez-Antón A, Jiménez-Gallo D,Millán-Cayetano JF, Navarro-Navarro I, Linares-Barrios M. Unilateral Lupus Mastitis.Lupus. 2023;32(3):438-440. doi:10.1177/09612033221151011.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

FDA restrict the sale of unapproved fluoride products; the AAP statement on leucovorin in ASD; at-home prenatal ultrasound; Kygevvi approved; Gazyva reduces SLE disease activity.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

From Pain to Wellness in PsA  IL-2 Therapy in SLE? Maybe  Sexual Function in axSpA  "Fact or Fiction: Trinetics Research at ACR"  CD1/BCMA Dual Targeting: One too many targets in SLE  Hydroxychloroquine Blood Levels  The Great Debate: AI in Rheumatology  Coping Strategies in axSpA  "What to do After First TNR Failure in axSpA" 

NSAID Addition Helps the Spine but not the Hips  Durability and Safety of Bimekizumab  Progressive BiTE in SLE 2  Hydroxychloroquine Reduces Autoantibody Levels  When the Back Hurts: uncovering BASDAI drivers in PsA  The Upper Hand in PsA? Not the Dominant One  Airway Disease in GPA  Wired for Success: Vagal Nerve Therapy in RA  GLP-1 in Knee Osteoarthritis  Disparities in Physical Function in SLE 

In this episode of the IC-DISC Show, I sit down with Randy from Trinity Bay Capital to talk about how specialized capital advisory bridges the gap between growing companies and the financing they actually need. Randy spent 17 years in traditional banking at First City and other institutions before moving into capital finance in the mid-1990s. His transition came from frustration with banking silos that prevented common-sense solutions for growing companies. After traveling extensively as a capital finance professional and later serving as president of a bank, he launched Trinity Bay Capital to help companies access everything from asset-based lending to purchase order financing. His approach differs from typical brokers because he pre-qualifies deals using his banking expertise, then targets just three carefully selected lenders rather than shotgunning dozens of institutions. What makes Randy's work compelling is how often he solves problems without charging fees. One client I referred received three competitive term sheets that gave him leverage to renegotiate with his existing bank, getting everything he wanted at no cost. Randy's focus on matching companies with conventional banks whenever possible, even when capital finance would pay higher fees, demonstrates how his business model prioritizes client outcomes over transaction volume. His internal 48-page reference guide of specialized lenders reflects decades of relationship-building across oil and gas, maritime, manufacturing, and distribution sectors. Randy's philosophy that "I don't need to work, I do this because I enjoy it" explains why 75% of his pipeline comes from Texas energy companies that conventional banks won't touch, and why he celebrates when clients find better deals elsewhere.     SHOW HIGHLIGHTS Randy turns down fund management opportunities that would pay more because accepting them would recreate the banking silos he left to escape. Trinity Bay Capital targets just three carefully selected lenders per deal instead of shotgunning 12-20 institutions, achieving 95% term sheet success rates. A construction mat company couldn't get financing because their primary assets wear out quickly, until Randy found lenders who advance directly on depreciating equipment. Randy helped a frack pipe manufacturer secure $30 million after eight conventional banks declined, simply by knowing which bank was allowed to do oil and gas deals. One client found a better deal independently, and Randy celebrated it instead of pushing his commission, telling him "as long as I can work with you, that's awesome." Randy's success fee from conventional banks is often reduced compared to capital finance companies, but he always takes clients there first because it's what they deserve.   Contact Details LinkedIn - Randy Gartz (https://www.linkedin.com/in/randygartz/) LINKSShow Notes Be a Guest About IC-DISC Alliance Randy GartzAbout Randy TRANSCRIPT (AI transcript provided as supporting material and may contain errors) Dave: Good morning, Randy. How are we today? Randy: We're doing great. How are you? Dave: I am doing great. Thank you. Where are you calling in from today? What part of the world are you in? Randy: Houston, Texas. Dave: Okay. Me as well. So I was just trying to think, how long have I known you? I think it's been over 20 years. Randy: It's been since the mid nineties. Dave: Has it been that long? Wow. So more like 30 years. Randy: Yes. Dave: We're getting old, my friend. Hey, I look a lot older than you did. That's subjective. So I've got some questions for you. Some I think I know the answer to, some I don't. Why don't we start? I'm a sequential learner. Let's start at the beginning. Where are you from originally? Are you from Southeast Texas? Originally? Randy: I'm an Air Force brat and I was born in El Paso, Texas. Dave: Okay. Randy: And we moved about every two years after that until I was in high school. Well, actually in high school I was at three different locations. And then starting from college on Texas a and an, I've been in Houston ever since. Dave: Why did I forget that you're in Aggie? Because where I went to school and I guess we've been able to get past that. Randy: I don't talk about that much. It's probably one of the main reasons a and m was good to me, but in my past. Dave: Yeah, no, I hear you. I'm just having fun with you. So I suppose moving every two years, that will help you learn rapport, building interpersonal skills, I suppose. Randy: Absolutely. That helped me go to city to city when I was traveling for capital finance companies and just introduce myself about a problem and just, hi, how are you? Who are you? What do you do? So yes, absolutely. Dave: So your degree from Texas a and m? Finance. Randy: Finance. And then I went to U of H and worked on an accounting degree. Dave: Okay. So what was your first job out of college? Randy: Oh, it was at credit training program for First City and Texas. Dave: Oh wow. They really had a great training program, didn't they? Randy: Two years long. Yeah, absolutely. We were working sometimes seven days a week and Saturday and Sunday the air conditioner wasn't working, wasn't on in building. And it's enough like it is today. Dave: No, I remember when I was at Arthur Anderson working one of our clients' weekends, those high rises had air conditioning on the weekends. You had to pay for it and we were not, were deemed worthy of air conditioning on the weekends. Randy: That's right. That's right. Dave: So you started out at traditional banking, Randy: Started at traditional banking, did that for about 17 years. First City and all of its precursors. First city in bank. Bank one, they finally sold to Chase. And then right after they sold to Chase, my manager at the time had gone to a capital finance company and he asked me to follow 'em. And that's when I got involved with Capital Finance. That was back in mid nineties. I enjoyed it. I enjoyed being on help companies. It wasn't like you're in silos at banks and the regulators can only allow you to do so much that there's so much more out there for companies to be able to provide them with growth capital, turnaround capital, acquisition capital that most people, most CFOs don't even know. And so I really enjoy that. I went back to conventional banking when I'm woman by the name of Mary Bass and I think you might know her. Dave: I know Mary. Yeah. Randy: She followed me for two years trying to get me to go to Redstone. Randy: Redstone was a small little bank. I didn't want to have anything to do with it. I didn't want to go to back to banking after I'd gone to Capital Finance and after two years of her calling me every two, three days a week when I was traveling three and a half weeks out of every month for four years Earth saying stuff like, rainy, where are you? When's the last time you saw your son pitch? When's the best time you were with your wife? What'd she do tonight? It's like, Mary, I'll interview. I've got to know that if I say no to this interview, you're not going to call me anymore. Well, I went on an interview, I met with David Chin Decker and he got me to go back to conventional finance and it was a good thing at the time, both he and Bob Hendrickson, who was president at the time of Redstone, had both grown up in the national division of First City's asset-based lending. Dave: That's Randy: What they were trying to bring over to this very small bank. We grew that bank from 58 million to 1,000,000,002 in three years. Dave: That is serious growth Randy: And most of those customers are still there. So it worked. But when you go on to other banks and all the silos that they have, you can't grow. You can't help companies as much as you would like if you know what's available. And I don't mean that to be mean to conventional bankers. Conventional bankers, I have all their respect or I respect them tremendously, but I just think that don't know what's still available. So Dave: It's Randy: Right going out there and trying to educate them to know, Hey listen, if you can't do this, here's what we can do. Dave: Yeah, no, I get it. And I know that as is typical in the banking business, most bankers don't serve at one bank for 40 years. There's always movement. And what I'd like to do though now is I'd like to skip forward to your May gig. I mean, I think the bottom line takeaway was your career was split between traditional corporate lending from the banker level all the way up to senior executive level. You've done the capital finance piece. It sounds like you wanted to create a new combination, new offering to the marketplace. So talk to me about what prompted you to start Trinity Bay Capital. Randy: I think, and I won't name his name, but I had just come back one day from booking an $85 million deal. I was by myself. I was doing all the settlement work. I was there for eight hours at this closing. And when I came back to the bank with all the paperwork and I walked in and I was really happy we got a large deal done, which eventually turned into a much larger deal. The first words out of my president's mouth was, Randy, any more deposits well understand. But this was a pretty good deal. And that together with all the silos that conventional banks have, the inability to do things that should be done, common sense things, but just conventional banks can do because of the regulators and because you can't put a hundred bankers out there and just let them be run out there and do everything they want to do. You can't do that makes conventional bankers conventional. But after being an capital financed group and also being at Redstone's Mezzanine and Equity Group, it taught me all the additional options that we have out there to be able to provide. So I thought at the time I was 63 years old, do I want to go to another bank? Am I tired of these silos? Yes, I am. I decided to just start my own company. I've been asked to take on funds and be able to lend our own money, but that would put me right back in the silos. Dave: Sure. Randy: I just enjoyed helping companies. It just makes me happy. And I wake up every morning, I come upstairs to my third floor office overlooking the bay and no silos, no having to sell every little credit card option that's out there. It just makes me happy. And so I know David, I don't know what I'd do if I retired. I never even considered it. I am enjoying what I'm doing now. I'm happy where I'm at and I'm happy making people happy. Dave: That is awesome. So help me understand who's like your ideal customer? What are the characteristics of the person you can help the most Randy: Fast growing companies, I mean, when you think of me as a broker, which I hate the term, there's 55,000 brokers out there. I trust five. Understood the difference. Lemme first start with the difference. The difference is that I've run credit departments, I've been on credit committees, I've been ping a bank. I know what banks can do and what they can't do. So when a bank can't do something, that is who should come to me, Dave: That Randy: Is who the banker should send me to. And it's not just because it's turnaround, it's not because they're in trouble. Maybe they're growing too fast, the lines of credit are going to be diminished, convince somebody just can't liven to leverage themselves up to the extent they need to take on the growth that they're seeing, acquisition growth where they're going to have to leverage your company with asset base collateral. Those are the type of things that we can do so we can actually help really good companies. For example, and unfortunately I say unfortunately for me it is, but 75% of my pipeline is oil and gas. I've been in Texas for 45 years. Oil and gas just follows here in Houston, Texas. And so just they call me that and maritime. So those two industries really can run our business alone. Although I would much rather have a lot of other manufacturer distribution and service companies than a lot of those companies. A lot of those CFOs owners of the companies, they have no clue what is available out there or why they can't get financing at the time. Maybe that's changing today, but at the time a lot of banks weren't allowed to venture into oil and gas. Oil and gas is a very cyclical industry, Randy: The ups and downs. If you don't do an oil and gas company in an asset based selection, you're bound to have trouble later on when the SLE falls because a lot of those assets can disappear. Randy: But on an asset based business, conventional banks can't do that. But not a lot of conventional banks are allowing their asset based lenders to do it today. So for example, I had a company that was a pipe manufacturer. They supplied from the pipe all the way to the dynamite and they had gone to eight different conventional banks, been declined every single time. When they came to me, I asked them, who'd you go to? Well, none of those guys have been to your deal because they're not allowed to. Their ownership was not allowing to do it. Took 'em to the first bank that I knew would do it, and we got that deal closed this year. A 30 million line of credit was with a $20 million accordion and well potential accordion they didn't need at the time because they were on the downhill run. But that bank knew how to do it. That bank, that lender knew how to do it. We knew who to go to. That deal got done. Dave: So let me just take a step back to make sure the audience understands. So your company doesn't actually yourself lend money. You're basically an intermediary between the capital markets, I guess primarily debt markets. Do you guys do any equity? Randy: We do some equity on the oil and gas side. I don't have that many providers on manufacturing distribution service, not oil and gas. Dave: It's mostly, yeah. And impart of what makes you unique is that you have, because of your background, you're able to match up the deal with the bank and want it simple Randy: For probably over 35 years. 35 years ago, a man by name of John Flatow at that time was at Briggs. Dave: Yeah, Randy: Put out this spreadsheet for me. And on the vertical column it had all of his customers on the horizontal column. It had everyone they could refer him to. What that did for me was realize that in the capital finance side where I was traveling throughout the United States, Canada, and sometimes Mexico, I was relating with so many financial providers and I've started taking down names and I've got a book, single page, probably 48 pages now of who does what likes, what their rates are, what their structure is. And so what makes us different than most other brokers is that, number one, I know what a bank can do and what they can't do. Randy: And when banks, we put together or I request all the financial information, all the documents that a banker would need in order that a financial officer would need, we put that together. We do our own pre-flight, which most all bankers now need to do to get credit to allow them to offer term sheets. We decide where the risk level is of each one of our customers after we decide if we can help 'em or not. Some customers don't have cash flow, they don't have collateral. Those two items combined make it a tough deal, impossible deal to do. But if they haven't waited too long, they're still survivable. There's so many options. We put together a pre-flight and then I go to that book and then we decide three up to three opportunities to take these financial providers. The difference between most brokers is most brokers don't know what they're looking at, don't know what's available, and they just chunking it out to 12 or 20 different institutions hoping something sticks. Randy: We go to three 95% of the time, we'll get three term sheets. Those are going to be at the right rate that the customer deserves and they're going to be the right structure. And then we take the closing and after closing, we help them negotiate or before closing, we help them negotiate the documents. We help 'em negotiate their term sheet and we get them through the entire process. Because most CFOs, well, I'm not going to say most, it's surprising how many CFOs don't know what's possible, don't know why a conventional bank can't help them and don't know why this other opportunity that's going to be 2% higher or more if the company's risk level is higher, why they have to do that. Many times, David, we'll have someone say, no, we're not going to take any of those term sheets. They're just too high. That that just doesn't make any sense to us. The structure's too tough, the administration's too tough. Okay, well get to more banks, go to more conventional banks, see if you can get your loan and if you can't come back, and that's where it's an education. It's an education that these CFOs need to go through it and they need to understand it to instruct their owners why they're doing what they're doing. Dave: And so you only get paid if you're able to successfully, Randy: We only get paid at closing at the closing table. We'll either obtain a success fee if it goes to conventional bank because if it goes to conventional bank, that's where I'm going to take it. That's what the client deserves. And it's always going to be a lower rate. It's always going to be less administration. And if I can do that, that's a win. Even though our fees are a lot of times going to be reduced because it's going to conventional bank and for that banker to be competitive, they can't pay our full fee. But if it goes to a capital finance company, the capital finance company is who's going to pay us. So the other doesn't have to pay us. If it goes to a capital finance company Dave: And if it goes to a bank are they Randy: Say bank, we need a success fee agreement Dave: From the Randy: We're going to be able to invoice the bank and at closing they'll pay us. Dave: Okay. So my listeners like stories. So let's talk about some examples. And again, I'm sure the client name will be anonymous, but give us just some stories to give us a sense of the types of deals that you guys can do. Randy: David, I'm going to throw out one that you referred to me yourself in front of some of your clients Dave: And Randy: We had a nice little discussion and at a later date, one of your clients called me for help. Dave: Yep, I know who you're talking about. Randy: Well, what we ended up doing is finding three other banks that could have helped him. Conventional banks. The client was definitely bank worthy, but his existing bank wasn't really working with him as much as they should have. While the client wanted the release of his personal guarantee at the size level that he was at, I had to educate him and convince him that since you're making every decision, you rule the company, you can do whatever you want to do with the company. They're going to want your personal guarantee to make sure that you stay in long. Randy: But that on the side, he deserved everything. He was, everything else he was asking for. He deserved a lower rate. He deserved a re amortization. So when he received the three term sheets that we provided him from other conventional banks, he went back to his existing bank and said, this is what I've got. And he got everything he was asking for the release of his personal guarantee. Well, he offered to pay me. There was nothing I could, I didn't do much. I didn't do anything extraordinary. It didn't take long to realize who he should be working with. So no charge. He went back to his original bank, got what he wanted and everybody's happy. So that's point. Dave: I know he was very appreciative of that. And that really goes to show the power or the ability you have to help clients. I mean, you effectively made a couple phone calls, I'm simplifying it, but you reached Randy: Out, it wasn't much more. Dave: You reached out to a couple people. You told 'em, Hey, this is a bankable deal. Their current banks may be taking advantage of 'em or doesn't see how bankable they really are, and this may be an opportunity for you. They threw out some turn sheets that was a wake up call for his current bank and they went ahead and because of the leverage he had of the other term sheets, his current bank suddenly became more reasonable Randy: And for no cost at all. He didn't have to get any appraisals, he didn't have to go through the underwriting process. The existing bank helped him. And yeah, bank that he was at is known as one of the most conventional banks in Texas. That's where he deserved to be because he deserved it. Dave: And I know of which bank you speak. Okay, well that's helpful. What about a deal, an example of somebody who wasn't as bankable and yet to go to the capital finance markets. Do you have an example of a deal like that? Randy: Sure. And it's not just because, I mean the company was doing well, but they were a provider of construction mats. So in other words, utilities are being put in, it's really muddy. It's been rainy. They provide their huge construction mats, large yellow equipment can go over, can drive over and not get stuck in the mud. Those mats are not that usable as collateral because they wear out real quick. Sure, sure. So who's going to do that? So we found a few companies that were willing to advance on those mats directly. Their existing company wasn't, their existing bank was not going to give them any more availability. If this company is growing and once we found them additional availability, the company has been able to grow. It's been able to find additional equity if they want it because once it started growing, they exists, said, I'm happy you're uncle and hunting. So they didn't want to do everything that we expected them to do was to go out and acquire other companies. We could have helped 'em grow to 200, $300 million. Dave: I've got you. Randy: Leon owner Dave: Just wasn't interested in Randy: All of a sudden the pressure was off his shoulders. I've got a great family, everything's taken care of. We're good. Dave: Okay. Randy: Now the issue with that is during the next dry season, he's not going to have the working capital to continue what he's doing. Dave: Right, right. Randy: He'll come back. Dave: Yeah. Randy: We expect that he'll come back. Dave: Okay. Randy: Is that what you were looking for? Dave: Yeah, yeah. Yeah. So I think you've kind of answered this question indirectly, but let me just ask you directly. So what is it that you enjoy the most about serving your clients in this capacity with your own gig? What do you enjoy the most about it? Randy: Well, even in my conventional bank days, I've always enjoyed ringing the bell and a deal gets done when we get a customer what he wants. And that is always endless. A struggle thing I can do. Dave: Yeah. Yeah. I knew that's what you were going to say. I know you John Flatow me, my wife. I mean we all relish serving customers in helping solve business problems for them. So that answer does not surprise me. Randy: Great. Dave: So that's coming from your perspective, what makes you different? What do your clients tell you about what makes you different? What are some feedback you've had from your clients? Randy: Well, we have an existing client right now that we're going to help him get purchase order financing Dave: And Randy: We're going to provide him an asset base loan and they purchase order facility on the side. And he found a conventional bank that agreed to do his deal that no other conventional bank would ever done at a fantastic rate, gave him 15 million instead of the 5 million he was asking for. Dave: Wow. Randy: Yeah. But he went there and he called me to tell me, Randy, I'm sorry I got bad news for you. I said, no, you found a great deal. As long as I can work with you. That is awesome. We'll get you the PO financing you take care of closing that deal at that bank and if they can't service it in the future, we'll take you back to through the banks that want to do it. Fact. That's great. That's still fine. So before he hung up, he said, Randy, you've really surprised me. I knew you wanted the sale of the asset based loan, but you're happy for me. You got the deal you wanted. I don't need to work. I do this, I enjoy it and it's I going to get the company the best thing I can get 'em. That kind of goes back to why did I start my own company, the stand my own company? Because conventional banks can't always do the common sense thing that the company means or we're doing it here. Dave: No, that is awesome. Yeah. I remember when you reached out to me and you started, I remembered thinking what a great fit, what great service you're offering that you're able to bring all of your expertise and because really what they're paying you for isn't your time, it's your knowledge is what they're really paying you for. They're not paying you for your time to reach out to 20 banks. A less the experienced person would do it is like the joke about the factory machinery that was down and they called in an engineer the story and he looked at it and he turned one screw, like half a turn and then gave him a $10,000 invoice and the owner was flabbergasted, why so much money? I need a detailed invoice. And his detailed invoice was turning the screw $1, knowing which screw to turn, $9,999. It's kind of the same way. Right? They're really paying you for your knowledge and your relationships, right? Randy: Correct. Absolutely. Dave: So what else, as we're kind of wrapping up here, what did I not ask you that you wish I had or I should have asked you? Randy: David, you're very good at what you do. You've asked me all the right questions. I've been able to tell you what we offer, why we're different, what we do. You've covered it. Okay, Dave: Well good. Well, I know you have helped many of my clients over the last 30 years in all of your different capacities, so I just wanted to thank you for that. You've always made me look good with my clients when I say, Hey, let me introduce you to Randy. Randy will take care of you. And that always makes me look good like this client, you had mentioned that you basically gave him leverage to renegotiate with his current bank. He'd been working on this problem for years and just was kind of hitting a wall because he sensed he could get a better deal, but he didn't really know how to go about that. He didn't really have the time and he didn't know if he just starts in the Yellow Pages. Well, I guess we don't have the yellow pages, but just starting at the eighties and just start calling all the banks. And then the problem is who you call at each bank. You can't just go to a retail branch and talk to the retail branch manager. So yes. Anyway, I appreciate over all these years you making me look like a star. Randy: You are one. David, I promise. Thank you for this opportunity. Dave: So I've got just one, two more questions and they're both fun. One is, if you could go back in time and give some advice to your 25 or 30-year-old self, what advice might you give to yourself Randy: And do what I'm doing now earlier? Dave: Yeah. That's the number one answer I get from my entrepreneur clients because almost, or my guest, almost all my guests had a similar path. They didn't just graduate from college and start their business. They didn't know, they didn't have any experience that always worked for somebody else for a while. Then they went on their own and they always have the same regret. They wish they'd been more courageous and done it sooner. So last one more. We're in Texas TexMex or barbecue? Randy: TexMex. Dave: Yeah. Randy: But worthy, I'll probably have both every week. Dave: Yeah. What's really good is if you find a place that's got great brisket tacos or brisket enchiladas, that kind of gives you a sense of both. So here's what a guest told me that I would have to agree with. He said it depends if it's average, I'm going to take the Tex-Mex. He goes, if I know that the option is too the barbecue place that's exceptional, and a Mexican restaurant that's exceptional, I take the barbecue because he said Tex-Mex has more capacity, more tolerance for average use, right? I mean, average Tex-Mex is still good, but average barbecue, not so much. Randy: I agree you 100%. Dave: That is great. Well, Randy, I really appreciate you taking time and I'm really excited to hear about what you're doing now and hopefully this episode will cost some people to reach out to you. We'll have your contact information in the show notes. So thanks again, Randy. Really appreciate it. Randy: Thank you David. Really appreciate it. Dave: There we have it. Another great episode. Thanks for listening in. If you want to continue the conversation, go to ic disc show.com. That's IC dash D-I-S-C-S-H-O w.com. And we have additional information on the podcast archived episodes as well as a button to be a guest. So if you'd like to be a guest, go select that and fill out the information and we'd love to have you on the show. So it we'll be back next time with another episode of the IC Disc Show. Special Guest: Randy Gartz.

Monreal asegura que Ley de Amparo será revisada sin retroactividad SMN alerta por lluvias intensas en el sureste del paísLeón XIV llama a la reconciliación frente a la crisis migratoriaMás información en nuestro podcast

Cette affaire est l'un des faits divers les plus célèbres et mystérieux de la France du XIXᵉ siècle. Elle mêle crimes sordides, rumeurs terrifiantes et un procès retentissant. Le décor : une auberge isoléeNous sommes sur le plateau du Gévaudan, en Haute-Loire, au début du XIXᵉ siècle. À l'époque, la route reliant Lyon à Toulouse est très fréquentée par des voyageurs, colporteurs et commerçants. Sur ce chemin se trouve une petite auberge isolée, tenue par Pierre et Marie Martin, un couple de paysans. Cette auberge, située à Peyrebeille, va bientôt devenir tristement célèbre sous le nom d'« Auberge rouge » en raison de la réputation sanglante qui l'entoure.Les rumeursTrès vite, des rumeurs commencent à circuler : des voyageurs y disparaissent mystérieusement. On raconte que les aubergistes attireraient leurs clients dans des chambres, puis les assommeraient avant de les dépouiller et de dissimuler les corps. L'imaginaire populaire évoquera même une sinistre méthode : un lit piégé basculant la victime dans une trappe, pour l'achever ensuite. Ces histoires terrifiantes, bien que jamais prouvées, forgent la légende noire de l'auberge.L'affaire éclateEn 1831, un colporteur est retrouvé mort non loin de Peyrebeille. Rapidement, les soupçons se tournent vers les époux Martin et leur domestique, Jean Rochette. L'enquête révèle que plusieurs disparitions pourraient être liées à l'auberge. Le couple est alors accusé d'avoir tué de nombreux voyageurs pour voler leur argent et leurs biens. Le chiffre de plus de cinquante victimes sera avancé par certains journaux de l'époque, mais il repose davantage sur des rumeurs et des exagérations que sur des preuves formelles.Le procèsLe procès s'ouvre en 1833 à Privas. Il passionne l'opinion publique, avide de sensations fortes. Les débats sont marqués par une forte charge émotionnelle et une presse avide de scandale. Les aubergistes sont décrits comme des monstres sans scrupules. Finalement, Pierre Martin, son épouse Marie et Jean Rochette sont condamnés à mort. Ils sont guillotinés le 2 octobre 1833 devant une foule considérable.Mythe ou réalité ?L'historiographie récente nuance beaucoup l'affaire. En réalité, les preuves contre les époux Martin étaient minces. Si leur culpabilité dans un ou deux meurtres paraît probable, l'image de tueurs en série méthodiques relève surtout de la légende, amplifiée par la presse et par l'imagination populaire. L'« Auberge rouge » est ainsi devenue un symbole : celui de la fascination morbide pour les crimes mystérieux dans la France du XIXᵉ siècle.HéritageAujourd'hui encore, l'auberge de Peyrebeille existe, transformée en musée. L'affaire continue d'inspirer livres, films et récits, entre réalité judiciaire et légende noire. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Dans cet épisode, on aborde un phénomène trop peu discuté mais pourtant central dans l'apprentissage du français et des langues étrangères : la fossilisation des erreurs.Depuis quelques années, un nouveau type de difficulté se fait entendre : les fautes de grammaire à l'oral. Elles ne sont pas de simples erreurs de débutant, mais des erreurs répétées, qui finissent par s'installer durablement dans la langue de l'apprenant… au point de devenir très difficiles à corriger.Les causes sont multiples :➡️La consommation excessive de contenus gratuits, sans suivi personnalisé➡️Le manque de correction régulière➡️Des enseignants peu formés ou trop peu expérimentésLe problème est que, lorsqu'une erreur se fossilise, le cerveau la considère comme correcte. Et la désapprendre demande beaucoup plus d'efforts. Un exemple concret : une élève prononce “alcool” [alku] au lieu de [alkool]. Malgré plusieurs corrections, son cerveau continue à revenir vers la mauvaise version.Alors, comment éviter ce piège ? La solution est simple, mais exigeante : travailler avec un professeur expérimenté. Lui seul peut repérer tes erreurs récurrentes, te corriger au bon moment et t'aider à désapprendre ce qui s'est enraciné dans ton français.Apprendre seul(e), sans cadre ni correction, peut sembler tentant, mais mène souvent à :➡️Trop de ressources dispersées➡️Manque de structure➡️Procrastination➡️Absence de progression mesurableBref, apprendre le français seul(e) est rarement efficace. L'accompagnement personnalisé fait toute la différence.Et toi, as-tu remarqué des erreurs fossilisées dans ton apprentissage du français ?Lien :Épisode 124 : Comment devenir polyglotte ? Avec Luca Lampariello“Le Français avec Yasmine” existe grâce au soutien des membres et élèves payants. 1️⃣ Le Club de Yasmine Le Club privé du podcast qui donne accès à toutes les transcriptions des épisodes, à 6 épisodes secrets par an, la newsletter privée en français et l'accès à la communauté des élèves et membres sur Discord. https://lefrancaisavecyasmine.com/club 2️⃣ Les livres du podcast Les transcriptions du podcast sont disponibles dans les livres sur Amazon : http://amazon.com/author/yasminelesire 3️⃣ Les cours de français avec YasmineRendez-vous sur le site de mon école pour découvrir le catalogue des cours disponibles : www.ilearnfrench.eu ➡️ Les réseaux sociaux Instagram : https://www.instagram.com/ilearnfrench/LinkedIn : https://www.linkedin.com/in/yasmine-lesire-ilearnfrench/ ➡️ Crédit musique La musique de cet épisode est créée par le groupe Beam. Merci à Maayan Smith et son groupe pour la musique. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Drs. Chaichian and Dall'Era review the updated guidelines for the treatment and management of SLE in children and adults.

In this episode of ACR Journals on Air, host Dr. Vicki Shanmugam speaks with Dr. Alain Sanchez-Rodriguez about a new study from the Lupus Midwest Network (LUMEN), published in Arthritis Care & Research. They explore how patients with systemic lupus erythematosus (SLE) experience delays and disparities in care, the types of physicians involved in diagnosis, and what the data reveals about access to specialized treatment. Dr. Sanchez-Rodriguez also shares his research journey and insights on improving equity in rheumatology. 

It's been over two decades since the American College of Rheumatology (ACR) last released comprehensive treatment guidelines for systemic lupus erythematosus (SLE), and much has changed. In this episode, we're joined by Dr. Lisa Sammaritano to discuss the forthcoming 2025 ACR Guidelines for the Treatment of SLE. These updated recommendations reflect a significant evolution in our approach to lupus care, from the growing range of therapeutic options to a stronger emphasis on patient engagement and minimizing steroid toxicity. We'll dive into how the guidelines tailor treatment across diverse organ systems and patient populations, and what clinicians need to know to effectively incorporate these updates into their practice. 

In this episode, CardioNerds Dr. Gurleen Kaur, Dr. Richard Ferraro, and Dr. Jake Roberts are joined by Cardio-Rheumatology expert, Dr. Monica Mukherjee, to discuss the role of utilizing multimodal imaging for cardiovascular disease risk stratification, monitoring, and management in patients with chronic systemic inflammation. The team delves into the contexts for utilizing advanced imaging to assess systemic inflammation with cardiac involvement, as well as the role of imaging in monitoring various specific cardiovascular complications that may develop due to inflammatory diseases. Audio editing by CardioNerds academy intern, Christiana Dangas. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Cardiovascular Multimodality Imaging & Systemic Inflammation Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk stratification, and implementation of therapeutic strategies to address these risks and disease-specific complications. As an example, patients with SLE have a 48-fold increased risk for developing ASCVD compared to the general population. They may also develop disease-specific complications, such as pericarditis, that require focused imaging approaches to detect. In addition to increasing the risk for CAD, systemic inflammatory diseases can also result in cardiac complications, including myocardial, pericardial, and valvular involvement. Assessment of these complications requires the use of different imaging techniques, with the modality and serial studies selected based on the suspected disease process involved. In most contexts, echocardiography remains the starting point for evaluating cardiac involvement in systemic inflammatory diseases and can inform the next steps in terms of diagnostic study selection for the assessment of specific cardiac processes. For example, if echocardiography is completed in an SLE patient and demonstrates potential myocardial or pericardial inflammation, the next steps in evaluation may include completing a cardiac MRI for better characterization. While no current guidelines or standards of care directly guide our selection of advanced imaging studies for screening and management of CVD in patients with systemic inflammatory diseases, our understanding of cardiac involvement in these patients continues to improve and will likely lead to future guideline development. Due to the vast heterogeneity of cardiac involvement both across and within different systemic inflammatory diseases, a personalized approach to caring for each individual patient remains central to CVD evaluation and management in these patients. For example, patients with systemic sclerosis and symptoms of shortness of breath may experience these symptoms due to a range of causes. Echocardiography can be a central guiding tool in assessing these patients for potential concerns related to pulmonary hypertension or diastolic dysfunction. Based on the initial echocardiogram, the next steps in evaluation may involve further ischemic evaluation or right heart catheterization, depending on the pathology of concern. Show notes - Cardiovascular Multimodality Imaging & Systemic Inflammation Episode notes drafted by Dr. Jake Roberts. What are the contexts in which we should consider pursuing multimodal cardiac imaging, and are there certain inflammatory disorders associated with systemic inflammation and higher associated CVD risk for which advanced imaging can help guide early intervention? Systemic inflammatory diseases are associated with elevated CVD risk, which has significant implications for early detection, risk stratification, prognostication, and implementation of therapeutic strategies to address CVD risk and complicat...